Dementia: Supporting people with dementia and their carers in health and social care

NICE guidelines [CG42] Published date:

Consultation on review proposal with stakeholders: 09 January 2012 - 23 January 2012

Review decision date: April 2012

Review decision: 

Review Decision: This guideline should not be updated at this time. For further information, please refer to the Surveillance Review Decision.

Next review date: March 2015

Summary of guidance

This guideline makes specific recommendations on Alzheimer's disease, dementia with Lewy bodies (DLB), frontotemporal dementia, vascular dementia and mixed dementias, as well as recommendations that apply to all types of dementia. Dementia in Parkinson's disease shares a number of similarities with DLB. Although the evidence base for dementia in Parkinson's disease was not examined specifically in the context of this guideline, the recommendations for DLB may be useful when considering treatments for dementia in Parkinson's disease. NICE has also produced a clinical guideline on Parkinson's disease (available from www.nice.org.uk/CG035).

The dementia guideline incorporates recommendations from NICE's technology appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.

  • April 2014: The wording of recommendation 1.4.3.2 has been changed to clarify the circumstances when imaging is needed.

    October 2012: Recommendation 1.7.2.5 has been updated, and a new recommendation 1.7.2.6 has been added, to incorporate recommendations from Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (NICE technology appraisal guidance 217). Subsequent recommendation numbers in this section have changed accordingly. The rest of the guideline remains unchanged.

    March 2011: The clinical guideline has been amended to incorporate Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (NICE technology appraisal guidance 217), which published in March 2011. See sections 1.6.2 and 1.6.3 for the updated information.

    October 2007: This guideline was amended to incorporate Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (NICE technology appraisal guidance 217), which published in March 2011. See sections 1.6.2, 1.6.3 and 1.7.2 for the updated information.

  • Get involved